1. HOME
  2. ABOUT US
    About Laekna Core Management Team Board of Directors Milestones Scientific Advisory Board Core Inverstors Honors & Awards
  3. R&D
    R&D Therapeutic Areas Candidates Pipeline Clinical Trials
  4. PARTNERSHIPS
    Strategic Partners Business Development Holistic Approach BD Contact
  5. INVESTORS
    Corporate Governance Financial Results Announcements and Circulars IR Calendar Listing Documents
  6. NEWS
    Press Releases Media Coverage
  7. CAREERS
    Global Team Career Development Jobs My Laekna
  8. CONTACT US
    Contact Us Leave Message
  9. RSS Feeds
NEWS
PRESS CENTER

Scroll down to see more

Latest Articles
Media Coverage Press Releases
Search
  1. 2021-06-25
    Laekna Therapeutics announces first patient enrolled in the clinical trial of innovative combination therapy for triple-negative breast cancer
    Laekna Therapeutics announces first patient enrolled in the clinical trial of innovative combination therapy for triple-negative breast cancer
    More
    More
    More
  2. 2022-03-24
    Laekna acquires exclusive global licenses to clinical-stage cancer asset
    More
  3. 2020-04-07
    Laekna closes $27.5 million series B funding
    More
  4. 2020-01-13
    Laekna to present at Biotech Showcase™ 2020 in San Francisco
    More
  5. 2018-12-14
    Laekna Therapeutics hosted on-site investigation by Shanghai Municipal Government
    More
  6. 2020-01-07
    Laekna Therapeutics LAE001 IND application was officially approved by CDE
    More
  7. 2018-10-22
    Laekna Therapeutics LAE001 IND application was officially accepted by CDE
    More
156789
Media contact
communication@laekna.com
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin

  1. HOME
  2. ABOUT US
  3. R&D
  4. PARTNERSHIPS
  5. INVESTORS
  6. INVESTORS
  7. NEWS
  8. CAREERS

Copyright © Laekna Therapeutics, All Rights Reserved.  Privacy Policy

Follow us on Linkedin

Follow us on Wechat